XIX International AIDS Conference in Washington D.C. Barton Haynes from the Duke Human Vaccine Institute (DHVI) has been working in the HIV vaccine field since 1985. Here he talks about the scientific difficulties of finding an HIV vaccine.

XIX International AIDS Conference in Washington D.C. Interview with the French Virologist, Françoise Barré-Sinoussi, winner of the Nobel Prize in Physiology or Medicine 2008 for discovering HIV as the cause of AIDS. Here she talks about the possibility of ending AIDS.

XIX International AIDS Conference in Washington D.C. Interview with the French Virologist, Françoise Barré-Sinoussi, winner of the Nobel Prize in Physiology or Medicine 2008 for discovering HIV as the cause of AIDS. Here she talks about the possibility of ending AIDS.

XIX International AIDS Conference. Sharon Lewin from Monash University in Melbourne discusses the possibilities of ending AIDS and scientific breakthroughs during the 30 years of the epidemic, for instance the discovery that some people are resistant to HIV.

XVII International AIDS Conference in Mexico City. Jeffrey Sturchio, Vice President of Merck & Co, talks about the development of protease inhibitors in 1996 and the relationship between the activists and the drug industry.

XVII International AIDS Conference in Mexico City. Jeffrey Sturchio, Vice President of Merck & Co, talks about the development of protease inhibitors in 1996 and the relationship between the activists and the drug industry.

Daria Hazuda from MSD explains the virology of HIV and talks about the past clinical studies on ARV, in particular integrase inhibitors, which she has been involved in. She also reflects on HIV as an exceptional virus and how to influence a new generation of HIV researchers.

David Klatzmann is a french immunologist who has been working in an AIDS group in France since 1981. He talks about the discoveries that CD4-antigens function as receptors for the HIV virus and explains the structure of this relationship in detail.

Luc Montagnier talks about the complex virology of HIV which makes the AIDS vaccine development so difficult. He also talks about the economic and cultural advantages of using traditional medicine as a part of the ARV therapy in developing countries.